Value of PSA screening test questioned

The test represents a significant decision dilemma for both patients and physicians. Some physicians believe it should be an annual ritual. Others aren't so sure.

By — Posted Oct. 11, 2004

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

G. Stephen Nace, MD, a general internist in Peoria, Ill., often ends up talking prostate-specific test results on Sundays after church. Men from the congregation come up to him and tell him their most recent scores from this common prostate cancer screening method.

"Guys talk about it," said the assistant professor of clinical medicine at the University of Illinois College of Medicine. "But I don't think many patients really appreciate the depth of the question and the issues involved. For most patients, it's just a blood test."

The test is one of the more controversial in medical circles, and this month, even one of the researchers who carried out much of the groundbreaking work to create it questioned whether it should be used at all.

"The PSA era is over in the United States," said Thomas Stamey, MD, professor of urology at Stanford University School of Medicine and lead author on the landmark paper in the Oct. 8, 1987, New England Journal of Medicine suggesting that rising PSA levels could be useful to detect and monitor prostate cancer.

Dr. Stamey's declaration came as part of his more recent paper published in the October Journal of Urology that offered a very different conclusion. In this study, he and his team analyzed tumors from more than 1,000 radical prostatectomies over the past 20 years. They determined that PSA testing was discovering smaller and smaller tumors that were less likely to be deadly. Thus, the conclusion: PSA levels are more indicative of whether the prostate is enlarged than if it is cancerous and needs to be treated.

"Our study raises a very serious question of whether a man should even use the PSA test for prostate cancer screening any more," Dr. Stamey said. "Our job now is to stop removing every man's prostate who has prostate cancer. We originally thought we were doing the right thing, but we are now figuring out how we went wrong. Some men need prostate treatment, but certainly not all of them."

Dr. Stamey's latest article supports the opinions of those physicians concerned that increased PSA test screening is leading to overtreatment of cancers that men are more likely to die with than of.

"This paper adds to a growing body of literature that seriously questions the use of PSA testing," said Timothy J. Wilt, MD, MPH, professor of medicine and a general internist at Minneapolis Veterans Affairs Center for Chronic Disease Outcomes and Research. "The fundamental point remains that it is still not known whether early detection with PSA testing reduces disease-specific morbidity or mortality. It's also not known whether early treatment improves length or quality of life."

But physicians who are hesitant about PSA testing -- a position consistent with the U.S. Preventive Services Task Force recommendations that say there is insufficient evidence to recommend it -- still find themselves in a difficult fix. The test is enormously popular among patients, even though its possible benefits are still controversial. But helping a patient sort through the debate and make a decision is a time-consuming challenge.

"I will go over the pros and cons, what's known and what's not known," Dr. Nace said. "But it depends so much on the individual patient."

It's also very likely that widespread PSA testing has benefited some men. It's just not clear who.

"It's helped some men, but we don't know in advance which men it will help," said Julie Mitchell, MD, assistant professor of medicine and a general internist at the Medical College of Wisconsin in Milwaukee. "It has also done some bad."

Disagreement in the ranks

Prostate cancer experts, many of whom are lobbying for annual screening of men past a certain age, responded angrily to Dr. Stamey's paper and expressed apprehension that some men might not come forward because of it.

"He's sending out a very unfortunate message," said William J. Catalona, MD, professor of urology and director of the clinical prostate cancer program at the Robert H. Lurie Comprehensive Cancer Center at Northwestern Memorial Hospital in Chicago. "It's wrong, and if patients give it credibility, it could cause some men to die a horrible death from prostate cancer."

Experts said finding ever-smaller tumors was evidence that population-wide screening was performing an effective job of improving prostate cancer outcomes, and that the adverse effects from treatment were worth the benefit of finding and detecting this form of cancer early.

"We got to a good place because of PSA screening," said Mark Garzotto, MD, associate professor of urology at the Oregon Health and Science University School of Medicine and a staff researcher at the Portland VA Medical Center. "Do we abandon the PSA because it's effective?"

But experts also agreed with Dr. Stamey's notion that the PSA test is far from the perfect screener and that a better test is needed to detect which prostate cancers are most likely to kill. Many are already using the rate of change in PSA numbers over time rather than the numbers themselves, and new tests are on the horizon.

"This data certainly does not signify the end of the use of PSA," said Michael J. Manyak, MD, chair of the Dept. of Urology at George Washington University. "We're going to see an evolution, not only in the use of PSA as it is now, but an evolution in the use of the 'sons of PSA,' if you will."

Back to top


Prostate cancer treatments linked to decreased function

Men treated for prostate cancer are less likely to be able to perform sexually and more likely to be incontinent after five years than men not diagnosed or treated for the disease, according to a study available online in September and appearing in print in the November issue of Cancer.

Researchers with the New Mexico Veterans Administration Health Care System in Albuquerque compared nearly 300 men with prostate cancer, most of whom received radical prostatectomy or radiotherapy, to more than 600 healthy controls matched for age and ethnicity.

After five years, both groups had similar bowel function and health-related quality-of-life scores, but only 41% of the men with cancer were continent. About 84% of those without cancer still had control of their bladders. Also, the number of those with cancer who said they had no erectile function problems declined from 45% to 8%. In the control group, that number declined only from 40% to 32%.

Authors of the paper concluded that the effects of prostate cancer treatments exceeded the impact of normal aging and this should be taken into account when making treatment decisions.

Back to top

External links

"The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years?," abstract, Journal of Urology, October (link)

"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate," abstract, New England Journal of Medicine, Oct. 8, 1987 (link)

Back to top



Read story

Confronting bias against obese patients

Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story

Read story


American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story

Read story

Policing medical practice employees after work

Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story

Read story

Diabetes prevention: Set on a course for lifestyle change

The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story

Read story

Medicaid's muddled preventive care picture

The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story

Read story

How to get tax breaks for your medical practice

Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story

Read story

Advance pay ACOs: A down payment on Medicare's future

Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story

Read story

Physician liability: Your team, your legal risk

When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story